Article

GDNF, NGF and BDNF as therapeutic options for neurodegeneration. Pharmacol Ther

Dorothy Hodgkin Building, Whitson St, Bristol BS1 3NY UK. Electronic address: .
Pharmacology [?] Therapeutics (Impact Factor: 9.72). 01/2013; 138(2). DOI: 10.1016/j.pharmthera.2013.01.004
Source: PubMed

ABSTRACT

Glial cell-derived neurotrophic factor (GDNF), and the neurotrophins nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) are important for the survival, maintenance and regeneration of specific neuronal populations in the adult brain. Depletion of these neurotrophic factors has been linked with disease pathology and symptoms, and replacement strategies are considered as potential therapeutics for neurodegenerative diseases such as Parkinson's, Alzheimer's and Huntington's disease. GDNF administration has recently been shown to be an effective treatment for Parkinson's disease, with clinical trials currently in progress. Trials with NGF for Alzheimer's disease are ongoing, with some degree of success. Preclinical results using BDNF also show much promise, although there are accompanying difficulties. Ultimately, the administration of a therapy involving proteins in the brain has inherent problems. Because of the blood-brain-barrier, the protein must be infused directly, produced by viral constructs, secreted from implanted protein-secreting cells or actively transported across into the brain. An alternative to this is the use of a small molecule agonist, a modulator or enhancer targeting the associated receptors. We evaluate these neurotrophic factors as potential short or long-term treatments, weighing up preclinical and clinical results with the possible effects on the underlying neurodegenerative process.

Download full-text

Full-text

Available from: Deborah Karen Shoemark
  • Source
    • "Studies on the use of various growth factors to promote peripheral nerve regeneration have gradually increased (Table 2), with an improved understanding of neurotrophic components that are released from nerve endings and their effect on nerve growth and differentiation. These neurotrophic factors, expressed at different intervals during nerve regeneration to accelerate axonal growth, include nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), ciliary neurotrophic factor (CNTF), and insulinlike growth factor-1 (IGF-1), all of which are secreted from Schwann cells[29]. Fibroblast growth factors (FGFs) have a significant role in cell growth and regeneration and are released from damaged nerve ending[30]. Subsequent studies have worked on combining FGF with structural components. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Patients with peripheral nerve injuries, especially severe injury, often face poor nerve regeneration and incomplete functional recovery, even after surgical nerve repair. This review summarizes treatment options of peripheral nerve injuries with current techniques and concepts and reviews developments in research and clinical application of these therapies.
    Full-text · Article · Jan 2016
  • Source
    • "Previous reports have suggested that in addition to cytokines, nitric oxide (NO) and neurotrophic factors, such as brain derived neurotrophic factor (BDNF), glial cell derived neurotrophic factor (GDNF) and nerve growth factor (NGF), might also contribute to the pathogenesis of CM (Gazzinelli et al., 2014; Jeney et al., 2014; Linares et al., 2013). Neurotrophic factors are a large group of growth factors essential for physiological functioning and the development of the nervous system (Allen et al., 2013). BDNF levels are reduced in the brains of humans with neurodegenerative diseases, such as Alzheimer disease (Zuccato and Cattaneo, 2009). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Plasmodium falciparum infection results in severe malaria in humans, affecting various organs, including the liver, spleen and brain, and resulting in high morbidity and mortality. The Plasmodium berghei ANKA (PbA) infection in mice closely recapitulates many aspects of human cerebral malaria (CM); thus, this model has been used to investigate the pathogenesis of CM. Suppressor of cytokine signaling 2 (SOCS2), an intracellular protein induced by cytokines and hormones, modulates the immune response, neural development, neurogenesis and neurotrophic pathways. However, the role of SOCS2 during CM remains unknown. SOCS2 knockout (SOCS2−/−) mice infected with PbA show an initial resistance to infection with reduced parasitemia and production of TNF, TGF-β, IL-12 and IL-17 in the brain. Interestingly, in the late phase of infection, SOCS2−/− mice display increased parasitemia and reduced Treg cell infiltration, associated with enhanced levels of Th1 and Th17 cells and related cytokines IL-17, IL-6, and TGF-β in the brain. A significant reduction in protective neurotrophic factors, such as glial cell line-derived neurotrophic factor (GDNF) and brain-derived neurotrophic factor (BDNF), was also observed. Moreover, the molecular alterations in the brain of infected SOCS2−/− mice were associated with anxiety-related behaviors and cognition impairment. Mechanistically, these results revealed enhanced nitric oxide (NO) production in PbA-infected SOCS2−/− mice, and the inhibition of NO synthesis through l-NAME led to a marked decrease in survival, the disruption of parasitemia control and more pronounced anxiety-like behavior. Treatment with l-NAME also shifted the levels of Th1, Th7 and Treg cells in the brains of infected SOCS2−/− mice to the background levels observed in infected WT, with remarkable exception of increased CD8+IFN+ T cells and inflammatory monocytes. These results indicate that SOCS2 plays a dual role during PbA infection, being detrimental in the control of the parasite replication but crucial in the regulation of the immune response and production of neurotrophic factors. Here, we provided strong evidence of a critical relationship between SOCS2 and NO in the orchestration of the immune response and development of CM during PbA infection.
    Full-text · Article · Jan 2016 · Brain Behavior and Immunity
  • Source
    • "This overcomes the challenges presented by the delivery of soluble proteins, providing a targeted source of growth factors for the neuroprotection of cells in and surrounding the injury site. Though there has been success in delivering genetic material for targeted therapeutic protein expression using viral vectors [3], there is a need to improve on this technology with a localised and efficient gene delivery method for future clinical applications [1] [15]. For this reason, the use of biomaterials as sophisticated tools to overcome these issues associated with viral vectors has acquired significant attention [1]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Viral vector gene delivery is a promising technique for the therapeutic administration of proteins to damaged tissue for the improvement of regeneration outcomes in various disease settings including brain and spinal cord injury, as well as autoimmune diseases. Though promising results have been demonstrated, limitations of viral vectors, including spread of the virus to distant sites, neutralization by the host immune system, and low transduction efficiencies have stimulated the investigation of biomaterials as gene delivery vehicles for improved protein expression at an injury site. Here, we show how Nfluorenylmethyloxycarbonyl (Fmoc) self-assembling peptide (SAP) hydrogels, designed for tissue-specific central nervous system (CNS) applications via incorporation of the laminin peptide sequence isoleucine–lysine–valine–alanine–valine (IKVAV), are effective as biocompatible, localized viral vector gene delivery vehicles in vivo. Through the addition of a C-terminal lysine (K) residue, we show that increased electrostatic interactions, provided by the additional amine side chain, allow effective immobilization of lentiviral vector particles, thereby limiting their activity exclusively to the site of injection and enabling focal gene delivery in vivo in a tissue-specific manner. When the C-terminal lysine was absent, no difference was observed between the number of transfected cells, the volume of tissue transfected, or the transfection efficiency with and without the Fmoc-SAP. Importantly, immobilization of the virus only affected transfection cell number and volume, with no impact observed on transfection efficiency. This hydrogel allows the sustained and targeted delivery of growth factors post injury. We have established Fmoc-SAPs as a versatile platform for enhanced biomaterial design for a range of tissue engineering applications.
    Full-text · Article · Nov 2015 · Nano Research
Show more